Year: 2020

Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indicationsFirst-in-class TDP-43 therapeutic and diagnostic programs advance as the target’s role in a newly defined form of age-related dementia, limbic-predominant age-related TDP-43 encephalopathy (LATE), gains prominence, with a highly competitive grant awardedAll clinical and preclinical programs remain on track to meet all milestones expected in 2020CHF 246.6 million in cash ensures operations are fully financed through Q1 2024             LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for Q3 2020 and...

Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose–limiting toxicitiesDetailed clinical data for each program to be presented at a medical conference in the first half of 2021CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both of its lead clinical programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), have achieved predefined criteria for advancement into combination and expansion stages of the ongoing Phase 1 trials. These criteria include safety, successful escalation to a biologically relevant dose, target engagement and meaningful pharmacodynamic activity in the ongoing Phase...

TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) announced today its financial results for the three months and nine months ended September 30, 2020 (“Q3 2020”).Q3 2020 HighlightsPortfolio continues to perform well through the COVID-19 pandemic with no material increase in delinquencies Generated $0.18 in distributable income per share and $0.17 adjusted net income per share as well as delivered a 98.3% distributable income payout ratio and a 102.5% adjusted net income payout ratio. Funded $89.4M on new and existing mortgages versus repayments of $145.8M.  This resulted in a reduction of net mortgage investments to $1,153.2M in Q3 2020.  The increase in repayments resulted in a Q3 turnover ratio of 12.3% versus 6.4% in Q2 and is a positive sign of increased market activity that will provide...

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented new clinical data that further evaluates the attack rate reductions, patient satisfaction and quality of life of hereditary angioedema (HAE) patients in the APeX-2 trial over 48 weeks. Berotralstat is an investigational treatment for the prevention of attacks in patients with HAE.The data from three abstracts, including a Distinguished Industry Oral Abstract, are being presented at the 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), which is being conducted virtually from November 13-15.“Presenting all available treatment options to patients is an important part of HAE clinical management. These data continue to demonstrate the potential of berotralstat as...

VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or “the Company”) is pleased to provide results from brownfields exploration drilling programs in Quebec, Greece, and Turkey, including an update on the newly-discovered Ormaque zone at Lamaque. Additionally, the Company is providing a brief update on COVID-19.Highlights in this release include:At Lamaque, new high-grade drill intercepts from the C2, C6 and C7 zones highlight the resource growth potential of the Triangle deposit; in addition, numerous new intercepts continue to grow the recent Ormaque zone discovery.At Efemcukuru, drill results have confirmed continuity of high gold grades within mineralized shoots at the Kokarpinar Middle and Kokarpinar South target areas, advancing this vein system to resource conversion drilling...

U Vast Resources plc / Ticker: VAST / Index: AIM / Sector: Mining13 November 2020Vast Resources plc(‘Vast’ or the ‘Company’)Update on first sale of concentrate at Baita PlaiVast Resources plc, the AIM-listed producer & development company, is pleased to update the market on progress at its Baita Plai Polymetallic Mine (‘Baita Plai’) in Romania.Following the previous announcements made on 22 & 26 October 2020 regarding the first sale of concentrate to Mercuria, the Company can confirm that it has copper concentrate prepared and ready for the first commercial delivery to the Port of Constanta in Romania. The Company awaits confirmation of the vessel arrival ahead of being able to formally announce the completion of the first sale to Mercuria.  The Company expects the formal completion of the first sale of concentrate to take place...

Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday, November 13, 2020, at 4:30 PM ET.In the 100 mg open label arm of MAESTRO-NAFLD:At week 16, MRI-PDFF (magnetic resonance imaging-proton density fat fraction) reduction compared to baseline was 53% overall (p

Intertrade Shipping AS har i dag kjøpt 148 461 aksjer i Vistin Pharma ASA til gjennomsnittskurs 16,25 per aksje. Intertrade Shipping AS eier etter kjøpet 11 075 000 aksjer i Vistin Pharma, tilsvarende 24.9% av selskapets utestående aksjer. Intertrade Shipping AS er kontrollert av Øyvin Brøymer som er Styreformann i Vistin Pharma ASA. 

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of an upsized underwritten public offering of 5,040,000 shares of its common stock at a price of $23.00 per share. All of the shares of common stock are being offered by ORIC. In addition, ORIC has granted the underwriters a 30-day option to purchase up to 756,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to ORIC from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ORIC, are expected to be approximately $115.9 million, excluding...

COPENHAGEN, Denmark, November 13, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) publishes corrected information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.About Bavarian NordicBavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name...